Disrupting KAT8 Liquid–Liquid Phase Separation with Hybrid Vesicle–Liposome Platform for Enhanced PD‐L1 Blockade Treatment
Advanced Materials · 2026-05 · 38 (25)
DOI: 10.1002/adma.202523584 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 01.04.2026. Verfasst von Xinyao Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Liposomes, Histone Acetyltransferases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: Shenzhen Medical Research Fund, National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Programmed cell death protein 1/its ligand 1 (PD‐1/PD‐L1) blockade has revolutionized cancer immunotherapy, yet its efficacy is limited by incomplete checkpoint inhibition and persistent PD‐L1 transcription. In this work, lysine acetyltransferase 8 (KAT8) is identified as a nucleator of liquid–liquid phase separation (LLPS)‐mediated condensates that concentrate transcription factors to drive sustained PD‐L1 transcription and promote immune resistance. Leveraging this mechanism, a PD‐1‐functionalized hybrid vesicle–liposome platform (PD‐1‐HVL–siKAT8) is developed to deliver small interfering RNA (siRNA) targeting KAT8 for LLPS modulation and enhanced cancer immunotherapy. In this platform, the PD‐1‐presenting vesicles enable tumor accumulation and PD‐L1 blockade, while the fused liposomes provide efficient siRNA encapsulation and cytosolic release, leading to potent KAT8 silencing and condensate dissolution. This LLPS modulator platform markedly suppresses PD‐L1 expression and reshapes the tumor immune microenvironment, augmenting type I interferon signaling, dendritic cell maturation, cytotoxic T‐cell activation, and M1‐like macrophage polarization. In subcutaneous and recurrent hepatocellular carcinoma models, PD‐1‐HVL–siKAT8 significantly inhibits tumor growth, prevents recurrence, and extends survival with negligible toxicity. Collectively, this approach integrates PD‐L1 blockade with disruption of LLPS‐dependent transcription for durable immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
- Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, China.
- Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
ORCID-Profile: Lang Rao
Förderung
- Shenzhen Medical Research Fund
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Hubei Provincial Natural Science Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
- Natural Science Foundation of Hubei Province
Zitieren
APA
Hu, X., Zhu, H., Meng, Q. F., He, X., Shen, Y., Xu, Y., Zhou, Z., Pan, Y., Xu, X., & Rao, L. (2026). Disrupting KAT8 Liquid–Liquid Phase Separation with Hybrid Vesicle–Liposome Platform for Enhanced PD‐L1 Blockade Treatment. Advanced Materials, 38(25). https://doi.org/10.1002/adma.202523584
Vancouver
Hu X, Zhu H, Meng QF, He X, Shen Y, Xu Y, et al. Disrupting KAT8 Liquid–Liquid Phase Separation with Hybrid Vesicle–Liposome Platform for Enhanced PD‐L1 Blockade Treatment. Advanced Materials. 2026;38(25). doi:10.1002/adma.202523584
BibTeX
@article{Hu2026,
author = {Hu, Xinyao and Zhu, Hua and Meng, Qian-Fang and He, Xiaoqin and Shen, Yang and Xu, Yangtao and Zhou, Zhuolin and Pan, Yuanwei and Xu, Ximing and Rao, Lang},
title = {Disrupting KAT8 Liquid–Liquid Phase Separation with Hybrid Vesicle–Liposome Platform for Enhanced PD‐L1 Blockade Treatment},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {25},
doi = {10.1002/adma.202523584}
}
EUVIMED